NCT04610580View on ClinicalTrials.gov

Bioavailability Study of 2 Oral Formulations of ALXN1840

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2021

Primary Completion Date

March 24, 2021

Study Completion Date

April 26, 2021

Conditions
Healthy
Interventions
DRUG

ALXN1840

ALXN1840 will be administered orally.

Trial Locations (1)

3004

Nucleus Network Pty Ltd., Melbourne

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY